Opioid tolerance and supersensitivity induce regional changes in the autoradiographic density of dihydropyridine-sensitive calcium channels in the rat central nervous system

被引:22
作者
Díaz, A [1 ]
Flórez, J [1 ]
Pazos, A [1 ]
Hurlé, MA [1 ]
机构
[1] Univ Cantabria, Fac Med, Dept Physiol & Pharmacol, Santander 39011, Spain
关键词
dihydropyridine binding sites; opioids; tolerance; supersensitivity; calcium channel blockers; autoradiography;
D O I
10.1016/S0304-3959(00)00249-9
中图分类号
R614 [麻醉学];
学科分类号
100217 ;
摘要
Chronic opioid administration induces adaptations in neurones resulting in opioid tolerance and dependence. The changes in dihydropyridine (DHP)-sensitive Ca2+ channels (L-type) associated with tolerance and supersensitivity to the antinociceptive effect of the mu-opioid receptor agonist sufentanil were analyzed in the central nervous system (CNS) of rats. Autoradiographic assays were performed with [H-3]PN-200-110 (isopropyl 4-(2,1,3-benzoxadiazol-4-yl)-1,4-dihydro-2,6-dimethyl-5-methoxycarbony. Chronic s.c. infusion of sufentanil (2 mu g/h) for 7 days, which has been shown to induce tolerance to the opioid antinociceptive effect, produced an upregulation of DHP binding sites. The highest increases in density were localized in regions involved in nociceptive transmission and perception, such as the dorsal horn of the spinal cord, the dorsal raphe nucleus, the central grey matter, the thalamic nuclei, and the somatosensory cortex. Animals were rendered supersensitive to the antinociceptive effect of sufentanil by chronic and simultaneous infusion of sufentanil (2 mu g/h) and nimodipine (1 mu g/h) for 7 days. Under these conditions, a greater increase in the number of DHP binding sites was observed in the spinal cord, central grey matter, dorsal raphe nucleus, and somatosensory neocortex, when compared to the sufentanil group. The role of an increased influx through L-type channels in opioid tolerance is reinforced, whereas their persistent blockade is essential for the expression of opioid supersensitivity. (C) 2000 International Association for the Study of Pain. Published by Elsevier Science B.V. All rights reserved.
引用
收藏
页码:227 / 235
页数:9
相关论文
共 47 条
[1]   EFFECT OF CLONIDINE, NIMODIPINE AND DILTIAZEM ON THE INVITRO OPIOID WITHDRAWAL RESPONSE IN THE GUINEA-PIG ILEUM [J].
ALFARO, MJ ;
COLADO, MI ;
LOPEZ, F ;
MARTIN, MI .
BRITISH JOURNAL OF PHARMACOLOGY, 1990, 101 (04) :958-960
[2]  
[Anonymous], OPIOIDS
[3]   CORTICAL DIHYDROPYRIDINE BINDING-SITES AND A BEHAVIORAL SYNDROME IN MORPHINE-ABSTINENT RATS [J].
ANTKIEWICZMICHALUK, L ;
MICHALUK, J ;
ROMANSKA, I ;
VETULANI, J .
EUROPEAN JOURNAL OF PHARMACOLOGY, 1990, 180 (01) :129-135
[4]   REDUCTION OF MORPHINE-DEPENDENCE AND POTENTIATION OF ANALGESIA BY CHRONIC COADMINISTRATION OF NIFEDIPINE [J].
ANTKIEWICZMICHALUK, L ;
MICHALUK, J ;
ROMANSKA, I ;
VETULANI, J .
PSYCHOPHARMACOLOGY, 1993, 111 (04) :457-464
[5]   EFFECTS OF PERIPHERAL AND CENTRAL ADMINISTRATION OF CALCIUM-CHANNEL BLOCKERS IN THE NALOXONE-PRECIPITATED ABSTINENCE SYNDROME IN MORPHINE-DEPENDENT RATS [J].
BAEYENS, JM ;
ESPOSITO, E ;
OSSOWSKA, G ;
SAMANIN, R .
EUROPEAN JOURNAL OF PHARMACOLOGY, 1987, 137 (01) :9-13
[6]   DIFFERENTIAL-EFFECTS OF CALCIUM-CHANNEL BLOCKERS AND STIMULANTS ON MORPHINE WITHDRAWAL INVITRO [J].
BARRIOS, M ;
BAEYENS, JM .
EUROPEAN JOURNAL OF PHARMACOLOGY, 1988, 152 (1-2) :175-178
[7]   CALCIUM-CHANNEL INHIBITORS SUPPRESS THE MORPHINE-WITHDRAWAL SYNDROME IN RATS [J].
BONGIANNI, F ;
CARLA, V ;
MORONI, F ;
PELLEGRINIGIAMPIETRO, DE .
BRITISH JOURNAL OF PHARMACOLOGY, 1986, 88 (03) :561-567
[8]   METAL-ION INTERACTIONS WITH OPIATES [J].
CHAPMAN, DB ;
WAY, EL .
ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY, 1980, 20 :553-579
[9]   EFFECT OF NIMODIPINE, DILTIAZEM AND BAY K-8644 ON THE BEHAVIORAL AND NEUROCHEMICAL CHANGES ASSOCIATED WITH NALOXONE-PRECIPITATED WITHDRAWAL IN THE RAT - A COMPARISON WITH CLONIDINE [J].
COLADO, MI ;
ALFARO, MJ ;
LOPEZ, F ;
DELVAL, V ;
MARTIN, MI .
GENERAL PHARMACOLOGY, 1993, 24 (01) :35-41
[10]   NEUROBIOLOGICAL MECHANISMS OF OPIOID TOLERANCE AND DEPENDENCE [J].
COLLIN, E ;
CESSELIN, F .
CLINICAL NEUROPHARMACOLOGY, 1991, 14 (06) :465-488